Phase II trial of cetuximab plus vinorelbine in previously untreated patients >70 with advanced NSCLC [non-small cell lung cancer]
Latest Information Update: 06 Aug 2009
Price :
$35 *
At a glance
- Drugs Cetuximab (Primary) ; Vinorelbine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Dec 2007 Status changed from in progress to completed.
- 06 Oct 2006 Status change
- 30 Oct 2005 New trial record.